• DOI:10.1016/S1474-4422(14)70129-2
Corpus ID: 28510979

Clinical trials in amyotrophic lateral sclerosis: why so many negative trials and how can trials be improved?

@article{Mitsumoto2014ClinicalTI,
  title={Clinical trials in amyotrophic lateral sclerosis: why so many negative trials and how can trials be improved?},
  author={H. Mitsumoto and B. Brooks and V. Silani},
  journal={The Lancet Neurology},
  year={2014},
  volume={13},
  pages={1127-1138}
}

H. Mitsumoto, B. Brooks, V. Silani

Published 2014

Medicine

The Lancet Neurology

Amyotrophic lateral sclerosis (ALS) is one of the most rapidly progressive neurodegenerative diseases of unknown cause. Riluzole is the only drug that slows disease progression. More than 50 randomised controlled trials (RCTs) of proposed disease-modifying drugs have failed to show positive results in the past half-century. In the past decade, at least 18 drugs have been tested in large phase 2 or 3 RCTs, including lithium, which was tested in several RCTs. Potential reasons for the negative… CONTINUE READING

View on Elsevier

doi.org

Save to Library

Create Alert

Cite

Launch Research Feed